Doxorubicine-Congestive Heart Failure-Increased Big Endothelin-1 Plasma Concentration: Reversal by Amlodipine, Losartan, and Gastric Pentadecapeptide BPC157 in Rat and Mouse

• Main Authors: Martina Lovric-Bencic (Author), Predrag Sikiric (Author), Jadranka S. Hanzevacki (Author), Sven Seiwerth (Author), Dunja Rogic (Author), Vesna Kusec (Author), Gorana Aralica (Author), Pasko Konjevoda (Author), Lovorka Batelja (Author), Alenka B. Blagaic (Author)
• Format: Book
• Published: Elsevier, 2004-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Overall, doxorubicine-congestive heart failure (CHF) (male Wistar rats and NMRI mice; 6 challenges with doxorubicine (2.5 mg/kg, i.p.) throughout 15 days and then a 4-week-rest period) is consistently deteriorating throughout next 14 days, if not reversed or ameliorated by therapy (/kg per day): a s...